<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MEROPENEM - meropenem injection, powder, for solution </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Meropenem for injection (I.V.) safely and effectively. See full prescribing information for Meropenem for injection (I.V.). <br><br>MEROPENEM FOR INJECTION, USP (I.V.)<br><br>Initial U.S. Approval: 1996<br><br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, Potential for Neuromotor Impairment (<a href="#i4i_section_id_162fbfa3-2777-46ce-a45d-68facaefe5df">5.10</a>) </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: </p>
<ul class="Disc">
<li>Complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (adult patients and pediatric patients ≥ 3 months only). (<a href="#i4i_section_id_01beabf2-9783-4f5c-a370-23386294744e">1.1</a>)</li>
<li>Complicated intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> (adult patients and pediatric patients ≥ 3 months only). (<a href="#i4i_section_id_c89680ab-494c-495c-9c80-a2b8950f6637">1.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">Bacterial meningitis</span> (pediatric patients ≥ 3 months only). (<a href="#i4i_section_id_d5f51096-248e-4931-88dd-194e120fcdfa">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<br><ul class="Disc">
<li>500 mg every 8 hours by intravenous infusion over 15 to 30 minutes for skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> for adult patients. (<a href="#i4i_section_id_18e4f140-baaa-4e69-a931-9322e22a44f8">2.1</a>)</li>
<li>1 g every 8 hours by intravenous infusion over 15 to 30 minutes for intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> for adult patients. (<a href="#i4i_section_id_18e4f140-baaa-4e69-a931-9322e22a44f8">2.1</a>)</li>
<li>1 g every 8 hours by intravenous bolus injection (5 to 20 mL) over 3 to 5 minutes for adult patients. (<a href="#i4i_section_id_18e4f140-baaa-4e69-a931-9322e22a44f8">2.1</a>)</li>
<li>Dosage should be reduced in adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_section_id_6861e0dc-0096-47e3-bf61-8fc1ca0fca12">2.2</a>)</li>
</ul>
<br><table border="0" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="3" valign="top">
<span class="Bold">Recommended Meropenem for injection (I.V.) Dosage Schedule for Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Creatinine Clearance (mL/min) </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Dose</span><br><span class="Bold">(dependent on type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>)</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">Dosing Interval </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">&gt; 50 <br>
</td>
<td class="Rrule" valign="top">Recommended dose (500 mg cSSSI and 1 g Intra-abdominal)<br>
</td>
<td class="Rrule" valign="top">Every 8 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">26-50 <br>
</td>
<td class="Rrule" valign="top">Recommended dose<br>
</td>
<td class="Rrule" valign="top">Every 12 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">10-25 <br>
</td>
<td class="Rrule" valign="top">One-half recommended dose<br>
</td>
<td class="Rrule" valign="top">Every 12 hours<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">&lt; 10 <br>
</td>
<td class="Rrule" valign="top">One-half recommended dose<br>
</td>
<td class="Rrule" valign="top">Every 24 hours<br>
</td>
</tr>
</tbody></table>
<ul class="Disc"><li>Pediatric patients ≥ 3 months of age. (<a href="#i4i_section_id_c4ad8392-c23c-41d4-89e5-14580958e423">2.3</a>)<span class="Bold"></span>
</li></ul>
<span class="Bold"><br></span><br><br><table border="0" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="4" valign="top">
<span class="Bold">Recommended Meropenem for injection (I.V.) Dosage Schedule for Pediatric Patients with Normal Renal Function</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Dose (mg/kg)</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">Up to a Maximum Dose</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">Dosing Interval</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Complicated skin and skin structure <br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">Every 8 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Intra-abdominal <br>
</td>
<td class="Rrule" align="center" valign="top">20<br>
</td>
<td class="Rrule" align="center" valign="top">1 g<br>
</td>
<td class="Rrule" align="center" valign="top">Every 8 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">40<br>
</td>
<td class="Rrule" align="center" valign="top">2 g<br>
</td>
<td class="Rrule" align="center" valign="top">Every 8 hours<br>
</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" colspan="4" valign="top">- Intravenous infusion is to be given over approximately 15 to 30 minutes.<br>- Intravenous bolus injection (5 to 20 mL) is to be given over approximately 3-5 minutes.<br>- There is no experience in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. <br>
</td></tr>
</tbody></table>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">500 mg Injection Vial (<a href="#i4i_dosage_form_strength_id_229352ae-f231-416a-8779-6921dd984ad6">3</a>) </p>
<p class="Highlighta">1 g Injection Vial (<a href="#i4i_dosage_form_strength_id_229352ae-f231-416a-8779-6921dd984ad6">3</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to product components or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to β-lactams. (<a href="#i4i_contraindications_id_ab8359a2-8b4f-440a-af20-73bdb2814aad">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported in patients receiving β-lactams (<a href="#i4i_section_id_1eebb073-b37b-4304-a676-4837f8cc5178">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> and other adverse CNS experiences have been reported during treatment. (<a href="#i4i_section_id_6ba8b3d9-5123-4c72-b5d8-6563c5aba826">5.2</a>)</li>
<li>Co-administration of Meropenem for injection (I.V.) with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. (<a href="#i4i_section_id_e50b455f-f975-4abe-8625-a2ab77af89f4">5.3</a>, <a href="#i4i_section_id_e5381a1d-23a1-46a6-a1b9-5e977d910c18">7.2</a>)</li>
<li>
<span class="Italics">Clostridium difficile-</span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (ranging from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>) has been reported. Evaluate if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#i4i_section_id_065c9412-d801-440d-83ba-8319218e44bc">5.4</a>)</li>
<li>In patients with renal dysfunction, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> has been observed. (<a href="#i4i_section_id_c619beb9-ff65-45f0-a8f8-b827cc4c9e9c">5.8</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥ 2%) are: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (<a href="#i4i_section_id_2c4a448d-6fe5-4a06-848d-725ba1696a5d">6.1</a>)  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA<span class="Bold">, LLC,</span> Vigilance &amp; Medical Affairs at 1-800-551-7176 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a> </span><span class="Bold">for voluntary reporting of adverse reactions.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Co-administration of Meropenem for injection (I.V.) with probenecid inhibits renal excretion of meropenem (<a href="#i4i_section_id_97f4b0d0-fd35-4526-9f7e-bb17234772cf">7.1</a>)</li>
<li>Co-administration of Meropenem for injection (I.V.) with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. (<a href="#i4i_section_id_e50b455f-f975-4abe-8625-a2ab77af89f4">5.3</a>, <a href="#i4i_section_id_e5381a1d-23a1-46a6-a1b9-5e977d910c18">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Dose adjustment is necessary, if creatinine clearance is 50 mL/min or less. (<a href="#i4i_section_id_6861e0dc-0096-47e3-bf61-8fc1ca0fca12">2.2</a>, <a href="#i4i_section_id_a3be5138-8fca-4c91-8fe6-58f96c048f1a">8.6</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (Adult Patients and Pediatric Patients ≥ 3 Months only)</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal Infections</span> (Adult Patients and Pediatric Patients ≥ 3 Months only)</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">Bacterial Meningitis</span> (Pediatric Patients ≥ 3 Months only)</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Use in Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Use in Pediatric Patients (≥ 3 Months only)</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Preparation of Solution</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Compatibility</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Stability and Storage</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Potential</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Interaction with Valproic Acid</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Clostridium difficile-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Development of Drug-Resistant Bacteria</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Overgrowth of Nonsusceptible Organisms</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Laboratory Tests</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Dialysis</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Potential for Neuromotor Impairment</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Adverse Reactions from Clinical Trials</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Probenecid</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Valproic Acid</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">Bacterial Meningitis</span></a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_4b200157-2177-4642-8389-deb16d3db58d"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Meropenem for injection (I.V.) is useful as presumptive therapy in the indicated condition (e.g., intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span>) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_01beabf2-9783-4f5c-a370-23386294744e"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (Adult Patients and Pediatric Patients ≥ 3 Months only)</h2>
<p class="First">Meropenem for injection (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Staphylococcus aureus</span> (methicillin-susceptible isolates only), <span class="Italics">Streptococcus pyogenes, Streptococcus agalactiae, </span>viridans group streptococci<span class="Italics">, Enterococcus faecalis </span>(vancomycin-susceptible isolates only),<span class="Italics"> Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, </span>and <span class="Italics">Peptostreptococcus</span> species.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c89680ab-494c-495c-9c80-a2b8950f6637"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal Infections</span> (Adult Patients and Pediatric Patients ≥ 3 Months only)</h2>
<p class="First">Meropenem for injection (I.V.) is indicated as a single agent therapy for the treatment of complicated <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> and <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> caused by viridans group streptococci, <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella pneumoniae</span>, <span class="Italics">Pseudomonas aeruginosa</span>, <span class="Italics">Bacteroides fragilis</span>, <span class="Italics">B. thetaiotaomicron</span>, and <span class="Italics">Peptostreptococcus </span>species.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d5f51096-248e-4931-88dd-194e120fcdfa"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">Bacterial Meningitis</span> (Pediatric Patients ≥ 3 Months only)</h2>
<p class="First">Meropenem for injection (I.V.) is indicated as a single agent therapy for the treatment of <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">bacterial meningitis</span> caused by <span class="Italics">Streptococcus pneumoniae</span><span class="Sup">‡</span>, <span class="Italics">Haemophilus influenzae</span> , and <span class="Italics">Neisseria meningitidis.</span></p>
<p><span class="Sup">‡</span> The efficacy of meropenem as monotherapy in the treatment of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> caused by penicillin nonsusceptible isolates of <span class="Italics">Streptococcus pneumoniae</span> has not been established.</p>
<p>Meropenem for injection (I.V.) has been found to be effective in eliminating concurrent <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> in association with <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">bacterial meningitis</span>.</p>
<p>For information regarding use in pediatric patients (3 months of age and older) [<span class="Italics">see Indications and Usage</span> (<a href="#i4i_section_id_01beabf2-9783-4f5c-a370-23386294744e">1.1</a>), (<a href="#i4i_section_id_c89680ab-494c-495c-9c80-a2b8950f6637">1.2</a>) or (<a href="#i4i_section_id_d5f51096-248e-4931-88dd-194e120fcdfa">1.3</a>); <span class="Italics">Dosage and Administration</span> (<a href="#i4i_section_id_f467264f-9234-47a4-874f-bfbcf2003fa4">2.3</a>), <span class="Italics">and Adverse Reactions </span>(<a href="#i4i_section_id_2c4a448d-6fe5-4a06-848d-725ba1696a5d">6.1</a>)].</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_047c99df-27fd-4037-ada0-084b8ff0d875"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_18e4f140-baaa-4e69-a931-9322e22a44f8"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Patients</h2>
<p class="First">The recommended dose of Meropenem for injection (I.V.) is 500 mg given every 8 hours for skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and 1 g given every 8 hours for intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span>. Meropenem for injection (I.V.) should be administered by intravenous infusion over approximately 15 to 30 minutes. Doses of 1 g may also be administered as an intravenous bolus injection (5 to 20 mL) over approximately 3-5 minutes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6861e0dc-0096-47e3-bf61-8fc1ca0fca12"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Use in Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage should be reduced in patients with creatinine clearance of 50 mL/min or less. (See dosing table below.)</p>
<br><p>When only serum creatinine is available, the following formula (Cockcroft and Gault equation)<span class="Sup">5</span> may be used to estimate creatinine clearance.</p>
<br><p>Males: Creatinine Clearance (mL/min) = <span class="Underline">Weight (kg) x (140 - age)</span>__</p>
<br><p>                                                                  72 x serum creatinine (mg/dL)</p>
<br><p>Females: 0.85 x above value<br><span class="Bold">Recommended Meropenem for injection (I.V.) Dosage Schedule for Adult Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<a name="id_4e27ea07-4b0e-4147-8edf-869f23009009"></a><table border="0" cellpadding="0" cellspacing="0" width="410">
<caption><span></span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top"> <br><span class="Bold">Creatinine Clearance</span><br> <br><span class="Bold">(mL/min)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Dose (dependent on type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Dosing Interval</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">&gt; 50<br>
</td>
<td class="Rrule" align="left" valign="top">Recommended dose (500 mg cSSSI and 1 g Intra-abdominal)<br>
</td>
<td class="Rrule" align="left" valign="top">Every 8 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">&gt; 25-50<br>
</td>
<td class="Rrule" align="left" valign="top">Recommended dose<br>
</td>
<td class="Rrule" align="left" valign="top">Every 12 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">10-25<br>
</td>
<td class="Rrule" align="left" valign="top">One-half recommended dose<br>
</td>
<td class="Rrule" align="left" valign="top">Every 12 hours<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">&lt; 10<br>
</td>
<td class="Rrule" align="left" valign="top">One-half recommended dose<br>
</td>
<td class="Rrule" align="left" valign="top">Every 24 hours<br>
</td>
</tr>
</tbody>
</table>
<p>There is inadequate information regarding the use of Meropenem for injection (I.V.) in patients on hemodialysis or peritoneal dialysis.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c4ad8392-c23c-41d4-89e5-14580958e423"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Use in Pediatric Patients (≥ 3 Months only)</h2>
<p class="First">For pediatric patients from 3 months of age and older, the Meropenem for injection (I.V.) dose is 10, 20 or 40 mg/kg every 8 hours (maximum dose is 2 g every 8 hours), depending on the type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (complicated skin and skin structure, intra-abdominal or <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>). (See dosing table below.) Pediatric patients weighing over 50 kg should be administered Meropenem for injection (I.V.) at a dose of 500 mg every 8 hours for complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, 1 g every 8 hours for intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> and 2 g every 8 hours for <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. Meropenem for injection (I.V.) should be given as intravenous infusion over approximately 15 to 30 minutes or as an intravenous bolus injection (5 to 20 mL) over approximately 3-5 minutes.</p>
<p>There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 g) bolus dose.<br><span class="Bold">Recommended Meropenem for injection (I.V.) Dosage Schedule for Pediatric Patients With Normal Renal Function</span></p>
<a name="id_92ad0afe-8524-44d6-a16c-79a663f7ba32"></a><table border="0" cellpadding="0" cellspacing="0" width="425">
<caption><span></span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" valign="top">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><br>
</td>
<td class="Rrule" align="center" valign="top">Dose (mg/kg)<br>
</td>
<td class="Rrule" align="center" valign="top">Up to a Maximum Dose<br>
</td>
<td class="Rrule" align="left" valign="top">Dosing Interval<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Complicated skin and skin structure <br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="left" valign="top">Every 8 hours<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Intra-abdominal <br>
</td>
<td class="Rrule" align="center" valign="top">20<br>
</td>
<td class="Rrule" align="center" valign="top">1 g<br>
</td>
<td class="Rrule" align="left" valign="top">Every 8 hours<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">40<br>
</td>
<td class="Rrule" align="center" valign="top">2 g<br>
</td>
<td class="Rrule" align="left" valign="top">Every 8 hours<br>
</td>
</tr>
</tbody>
</table>
<p>There is no experience in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.<br><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c263ffdf-99c3-403c-a8c8-f01b3230b5ec"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Preparation of Solution</h2>
<p class="First"><span class="Bold">For Intravenous Bolus Administration</span></p>
<br><p>Constitute injection vials (500 mg and 1 g) with sterile Water for Injection. (see table below.) Shake to dissolve and let stand until clear. </p>
<br><a name="id_9d1d9ac5-4494-4cc0-8dd4-cfed4669126f"></a><table border="0" cellpadding="0" cellspacing="0" width="337"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top"> <br> <br> <br>            Vial size            <br>
</td>
<td class="Rrule" align="center" valign="top">Amount of Diluent Added (mL)<br>
</td>
<td class="Rrule" align="center" valign="top">Approximate Withdrawable Volume (mL)<br>
</td>
<td class="Rrule" align="center" valign="top">Approximate Average Concentration (mg/mL)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">500 mg<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">50<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">1 g<br>
</td>
<td class="Rrule" align="center" valign="top">20<br>
</td>
<td class="Rrule" align="center" valign="top">20<br>
</td>
<td class="Rrule" align="center" valign="top">50<br>
</td>
</tr>
</tbody></table>
<p><span class="Bold">For Infusion</span></p>
<br><p>Infusion vials (500 mg and 1 g) may be directly constituted with a compatible infusion fluid. Alternatively, an injection vial may be constituted, then the resulting solution added to an I.V. container and further diluted with an appropriate infusion fluid [<span class="Italics">see Dosage and Administration</span> (<a href="#i4i_section_id_f467264f-9234-47a4-874f-bfbcf2003fa4">2.5</a>) <span class="Italics">and </span>(<a href="#i4i_section_id_166cc40e-63d7-49e3-951a-1593d090ac25">2.6</a>)].</p>
<br><p><span class="Bold">WARNING: Do not use flexible container in series connections.</span></p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f467264f-9234-47a4-874f-bfbcf2003fa4"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Compatibility</h2>
<p class="First">Compatibility of Meropenem with other drugs has not been established. Meropenem should not be mixed with or physically added to solutions containing other drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_166cc40e-63d7-49e3-951a-1593d090ac25"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Stability and Storage</h2>
<p class="First">Freshly prepared solutions of Meropenem should be used whenever possible. However, constituted solutions of Meropenem maintain satisfactory potency at controlled room temperature 15-25°C (59-77°F) or under refrigeration at 4°C (39°F) as described below. Solutions of intravenous Meropenem should not be frozen.</p>
<p><span class="Bold">Intravenous Bolus Administration</span></p>
<p>Meropenem injection vials constituted with sterile Water for Injection for bolus administration (up to 50 mg/mL of Meropenem) may be stored for up to 2 hours at controlled room temperature 15-25°C (59-77°F) or for up to 12 hours at 4°C (39°F).</p>
<p><span class="Bold">Intravenous Infusion Administration</span></p>
<p><span class="Bold">Stability in Infusion Vials:</span> Meropenem infusion vials constituted with Sodium Chloride Injection 0.9% (Meropenem concentrations ranging from 2.5 to 50 mg/mL) are stable for up to 2 hours at controlled room temperature 15-25°C (59-77°F) or for up to 18 hours at 4°C (39°F). Infusion vials of Meropenem constituted with Dextrose Injection 5% (Meropenem concentrations ranging from 2.5 to 50 mg/mL) are stable for up to 1 hour at controlled room temperature 15-25°C (59-77°F) or for up to 8 hours at 4°C (39°F).</p>
<p><span class="Bold">Stability in Plastic I.V. Bags:</span> Solutions prepared for infusion (Meropenem concentrations ranging from 1 to 20 mg/mL) may be stored in plastic intravenous bags with diluents as shown below:</p>
<a name="id_f50e0df5-bf2a-4393-8277-e9073a8978a4"></a><table border="0" cellpadding="0" cellspacing="0" width="461"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="justify" valign="top"></td>
<td class="Rrule" align="center" valign="top">Number of Hours Stable at Controlled Room Temperature 15-25°C (59-77°F)<br>
</td>
<td class="Rrule" align="center" valign="top">Number of Hours Stable at 4°C (39°F)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Sodium Chloride Injection 0.9%<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">24<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Dextrose Injection 5%<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Dextrose Injection 10%<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Dextrose and Sodium Chloride Injection 5% / 0.9%<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Dextrose and Sodium Chloride Injection 5% / 0.2%<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Potassium Chloride in Dextrose Injection 0.15% / 5%<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> in Dextrose Injection 0.02% / 5%<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Dextrose Injection 5% in Normosol<span class="Sup">®</span>-M<span class="Sup">1</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Dextrose Injection 5% in Ringers Lactate Injection<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Dextrose and Sodium Chloride Injection 2.5% / 0.45%<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">12<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Mannitol Injection 2.5%<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">16<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Ringers Injection<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">24<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Ringers Lactate Injection<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">12<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Sodium Lactate Injection 1/6 N<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">24<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Injection 5%<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">1</span>NORMOSOL is a registered trademark of Hospira Inc.</p>
<p><span class="Bold">Stability in Baxter Minibag Plus:</span> Solutions of Meropenem (Meropenem concentrations ranging from 2.5 to 20 mg/mL) in Baxter Minibag Plus bags with Sodium Chloride Injection 0.9% may be stored for up to 4 hours at controlled room temperatures 15-25°C (59-77°F) or for up to 24 hours at 4°C (39°F). Solutions of Meropenem (Meropenem concentrations ranging from 2.5 to 20 mg/mL) in Baxter Minibag Plus bags with Dextrose Injection 5% may be stored up to 1 hour at controlled room temperatures 15-25°C (59-77°F) or for up to 6 hours at 4°C (39°F).</p>
<p><span class="Bold">Stability in Plastic Syringes, Tubing and Intravenous Infusion Sets:</span> Solutions of Meropenem (Meropenem concentrations ranging from 1 to 20 mg/mL) in Water for Injection or Sodium Chloride Injection 0.9% (for up to 4 hours) or in Dextrose Injection 5% (for up to 2 hours) at controlled room temperatures 15-25°C (59-77°F) are stable in plastic tubing and volume control devices of common intravenous infusion sets.</p>
<p>Solutions of Meropenem (Meropenem concentrations ranging from 1 to 20 mg/mL) in Water for Injection or Sodium Chloride Injection 0.9% (for up to 48 hours) or in Dextrose Injection 5% (for up to 6 hours) are stable at 4°C (39°F) in plastic syringes.</p>
<p><span class="Bold">NOTE:</span> Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_229352ae-f231-416a-8779-6921dd984ad6"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Single use clear glass vials containing 500 mg or 1 g (as the trihydrate blend with anhydrous sodium carbonate for constitution) of sterile meropenem powder.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_ab8359a2-8b4f-440a-af20-73bdb2814aad"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Meropenem for injection (I.V.) is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product or to other drugs in the same class or in patients who have demonstrated <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to β-lactams.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_8d3a275d-c5e0-4d96-8cc5-78ac95499ea8"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1eebb073-b37b-4304-a676-4837f8cc5178"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported in patients receiving therapy with β-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens.</p>
<p>There have been reports of individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> who have experienced severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> when treated with another β-lactam. Before initiating therapy with Meropenem for injection (I.V.), careful inquiry should be made concerning previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to penicillins, cephalosporins, other β-lactams, and other allergens. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to Meropenem for injection (I.V.) occurs, discontinue the drug immediately. Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> require immediate emergency treatment with epinephrine, oxygen, intravenous steroids, and airway management, including intubation. Other therapy may also be administered as indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ba8b3d9-5123-4c72-b5d8-6563c5aba826"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Potential</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> and other adverse CNS experiences have been reported during treatment with Meropenem for injection (I.V.) These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>) or with <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">bacterial meningitis</span> and/or compromised renal function [<span class="Italics">see Adverse Reactions</span> (<a href="#i4i_section_id_2c4a448d-6fe5-4a06-848d-725ba1696a5d">6.1</a>) <span class="Italics">and Drug Interactions</span> (<a href="#i4i_section_id_e5381a1d-23a1-46a6-a1b9-5e977d910c18">7.2</a>)].</p>
<p>During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with the overall <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rate being 0.7% (based on 20 patients with this adverse event). All meropenem-treated patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> had pre-existing contributing factors. Among these are included prior history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or CNS abnormality and concomitant medications with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> potential. Dosage adjustment is recommended in patients with advanced age and/or reduced renal function. [<span class="Italics">see Dosage and Administration </span>(<a href="#i4i_section_id_6861e0dc-0096-47e3-bf61-8fc1ca0fca12">2.2</a>)].</p>
<p>Close adherence to the recommended dosage regimens is urged, especially in patients with known factors that predispose to convulsive activity. Anti-convulsant therapy should be continued in patients with known <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders. If focal <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occur, patients should be evaluated neurologically, placed on anti-convulsant therapy if not already instituted, and the dosage of Meropenem for injection (I.V.) re-examined to determine whether it should be decreased or the antibiotic discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e50b455f-f975-4abe-8625-a2ab77af89f4"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Interaction with Valproic Acid</h2>
<p class="First">Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction. The concomitant use of meropenem and valproic acid or divalproex sodium is generally not recommended. Antibacterials other than carbapenems should be considered to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in patients whose <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are well controlled on valproic acid or divalproex sodium. If administration of Meropenem for injection (I.V.) is necessary, supplemental anti-convulsant therapy should be considered [<span class="Italics">see Drug Interactions</span> (<a href="#i4i_section_id_e5381a1d-23a1-46a6-a1b9-5e977d910c18">7.2</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_065c9412-d801-440d-83ba-8319218e44bc"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Clostridium difficile-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Clostridium difficile-</span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Meropenem for injection (I.V.), and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing isolates of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile, </span>and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bc035094-82ad-40ac-a1ec-f37ce23aa80f"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Development of Drug-Resistant Bacteria</h2>
<p class="First">Prescribing Meropenem for injection (I.V.) in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1c24350e-ae2f-43cc-b740-dabad252916d"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Overgrowth of Nonsusceptible Organisms</h2>
<p class="First">As with other broad-spectrum antibiotics, prolonged use of meropenem may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patient is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> does occur during therapy, appropriate measures should be taken.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_140a183e-5520-4daf-8906-84c96cd6fd9e"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Laboratory Tests</h2>
<p class="First">While Meropenem for injection (I.V.) possesses the characteristic low toxicity of the beta-lactam group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, is advisable during prolonged therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c619beb9-ff65-45f0-a8f8-b827cc4c9e9c"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> has been observed but no clinical <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reported [<span class="Italics">see Dosage and Administration</span> (<a href="#i4i_section_id_6861e0dc-0096-47e3-bf61-8fc1ca0fca12">2.2</a>), <span class="Italics">Adverse Reactions</span> (<a href="#i4i_section_id_2c4a448d-6fe5-4a06-848d-725ba1696a5d">6.1</a>), <span class="Italics">Use In Specific Populations</span> (<a href="#i4i_geriatric_use_id_6b89a087-4cb1-434a-bd9c-96f237d4d68b">8.5</a>) and (<a href="#i4i_section_id_a3be5138-8fca-4c91-8fe6-58f96c048f1a">8.6</a>), and <span class="Italics">Clinical Pharmacology </span>(<a href="#i4i_pharmacokinetics_id_ac6e3acf-3798-4404-a549-3d17d180f57c">12.3</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66993d59-1454-4cb8-a71b-b51c86d93243"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Dialysis</h2>
<p class="First">There is inadequate information regarding the use of Meropenem for injection (I.V.) in patients on hemodialysis or peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_162fbfa3-2777-46ce-a45d-68facaefe5df"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Potential for Neuromotor Impairment</h2>
<p class="First">Patients receiving Meropenem for injection (I.V.) on an outpatient basis may develop adverse events such as <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and/or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> that could interfere with mental alertness and/or cause motor impairment. Until it is reasonably well established that Meropenem for injection (I.V.) is well tolerated, patients should not operate machinery or motorized vehicles [see <span class="Italics">Adverse Reactions</span> (<a href="#i4i_section_id_2c4a448d-6fe5-4a06-848d-725ba1696a5d">6.1</a>)].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_b2a5ca7d-5d69-4209-befc-75cc3da8c197"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following are discussed in greater detail in other sections of labeling:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_1eebb073-b37b-4304-a676-4837f8cc5178">5.1</a>)]</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Potential [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_6ba8b3d9-5123-4c72-b5d8-6563c5aba826">5.2</a>)]</li>
<li>Interaction with Valproic Acid [<span class="Italics">see Warnings and Precautions </span>(<a href="#i4i_section_id_e50b455f-f975-4abe-8625-a2ab77af89f4">5.3</a>)]</li>
<li>
<span class="Italics">Clostridium difficile</span> – Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_065c9412-d801-440d-83ba-8319218e44bc">5.4</a>)]</li>
<li>Development of Drug-Resistant Bacteria [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_bc035094-82ad-40ac-a1ec-f37ce23aa80f">5.5</a>)]</li>
<li>Overgrowth of Nonsusceptible Organisms [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_1c24350e-ae2f-43cc-b740-dabad252916d">5.6</a>)]</li>
<li>Laboratory Tests [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_140a183e-5520-4daf-8906-84c96cd6fd9e">5.7</a>)]</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_c619beb9-ff65-45f0-a8f8-b827cc4c9e9c">5.8</a>)]</li>
<li>Dialysis [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_66993d59-1454-4cb8-a71b-b51c86d93243">5.9</a>)]</li>
<li>Potential for Neuromotor Impairment [see<span class="Italics"> Warnings and Precautions</span> (<a href="#i4i_section_id_162fbfa3-2777-46ce-a45d-68facaefe5df">5.10</a>)]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c4a448d-6fe5-4a06-848d-725ba1696a5d"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Adverse Reactions from Clinical Trials</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Bold"><span class="Underline">Adult Patients:</span></span></p>
<p>During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with Meropenem for injection (I.V.) (500 mg or 1000 mg every 8 hours). <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> in 5 patients were assessed as possibly related to meropenem; 36 (1.2%) patients had meropenem discontinued because of adverse events. Many patients in these trials were severely ill and had multiple background diseases, physiological impairments and were receiving multiple other drug therapies. In the seriously ill patient population, it was not possible to determine the relationship between observed adverse events and therapy with Meropenem for injection (I.V.).</p>
<p>The following adverse reaction frequencies were derived from the clinical trials in the 2904 patients treated with Meropenem for injection (I.V.)</p>
<p><span class="Bold">Local Adverse Reactions</span></p>
<p>Local adverse reactions that were reported irrespective of the relationship to therapy with Meropenem for injection (I.V.) were as follows:</p>
<p><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> at the injection site 2.4%</p>
<p><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span> 0.9%</p>
<p><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span>/<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> 0.8%</p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> at the injection site 0.4%</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> at the injection site 0.2%</p>
<p><span class="Bold">Systemic Adverse Reactions</span></p>
<p>Systemic adverse reactions that were reported irrespective of the relationship to Meropenem for injection (I.V.) occurring in greater than 1% of the patients were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (4.8%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (3.6%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2.3%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1.9%), <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (1.6%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (1.4%), <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (1.3%), <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> (1.2%), and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (1.2%).</p>
<p>Additional systemic adverse reactions that were reported irrespective of relationship to therapy with Meropenem for injection (I.V.) and occurring in less than or equal to 1% but greater than 0.1% of the patients are listed below within each body system in order of decreasing frequency:</p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events were seen as follows: <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> (0.5%), <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span> (0.3%), <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> (0.2%), <span class="product-label-link" type="condition" conceptid="194690" conceptname="Nontraumatic hemoperitoneum">hemoperitoneum</span> (0.2%), summing to 1.2%.</p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, abdominal enlargement, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span></p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">heart arrest</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span></p>
<p><span class="Bold">Digestive System:</span> <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span></p>
<p><span class="Bold">Hemic/Lymphatic:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">hypochromic anemia</span>, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span></p>
<p><span class="Bold">Metabolic/Nutritional:</span> <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span></p>
<p><span class="Bold">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>/<span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_6ba8b3d9-5123-4c72-b5d8-6563c5aba826">5.2</a>) and (<a href="#i4i_section_id_162fbfa3-2777-46ce-a45d-68facaefe5df">5.10</a>)]</p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">lung edema</span></p>
<p><span class="Bold">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span></p>
<p><span class="Bold">Urogenital System:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal moniliasis</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span></p>
<p><span class="Bold">Adverse Laboratory Changes</span></p>
<p>Adverse laboratory changes that were reported irrespective of relationship to Meropenem for injection (I.V.) and occurring in greater than 0.2% of the patients were as follows:</p>
<p><span class="Bold">Hepatic:</span> increased SGPT (ALT), <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST), alkaline phosphatase, LDH, and bilirubin</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">increased platelets</span>, increased eosinophils, decreased platelets, <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span>, decreased hematocrit, decreased WBC, shortened <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time and shortened partial thromboplastin time, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span></p>
<p><span class="Bold">Renal:</span> increased creatinine and increased BUN</p>
<p><span class="Bold">NOTE: </span>For patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the incidence of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> reported irrespective of relationship to Meropenem for injection (I.V.), increased in patients with moderately severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &gt; 10 to 26 mL/min) [<span class="Italics">see Dosage and Administration</span> (<a href="#i4i_section_id_6861e0dc-0096-47e3-bf61-8fc1ca0fca12">2.2</a>), <span class="Italics">Warnings and Precautions</span> (<a href="#i4i_section_id_c619beb9-ff65-45f0-a8f8-b827cc4c9e9c">5.8</a>), <span class="Italics">Use in Specific Populations</span> (<a href="#i4i_geriatric_use_id_6b89a087-4cb1-434a-bd9c-96f237d4d68b">8.5</a>) and (<a href="#i4i_section_id_a3be5138-8fca-4c91-8fe6-58f96c048f1a">8.6</a>) <span class="Italics">and</span><span class="Italics">Clinical Pharmacology </span>(<a href="#i4i_pharmacokinetics_id_ac6e3acf-3798-4404-a549-3d17d180f57c">12.3</a>)].</p>
<p><span class="Bold">Urinalysis:</span> presence of red blood cells</p>
<p><span class="Bold">Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<p>In a study of complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the adverse reactions were similar to those listed above. The most common adverse events occurring in &gt; 5% of the patients were: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (7.8%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (7.8%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (7%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (7%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (5.5%), and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (5.1%). Adverse events with an incidence of &gt; 1%, and not listed above, include: <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disorder</span>, and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</p>
<p><span class="Bold"><span class="Underline">Pediatric Patients</span></span></p>
<p><span class="Bold">Clinical Adverse Reactions</span></p>
<p>Meropenem for injection (I.V.) was studied in 515 pediatric patients (≥ 3 months to &lt; 13 years of age) with serious <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> (excluding <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, see next section.) at dosages of 10 to 20 mg/kg every 8 hours. The types of clinical adverse events seen in these patients are similar to the adults, with the most common adverse events reported as possibly, probably, or definitely related to Meropenem for injection (I.V.) and their rates of occurrence as follows:</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> 3.5%</p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> 1.6%</p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> 0.8%</p>
<p>Meropenem for injection (I.V.) was studied in 321 pediatric patients (≥ 3 months to &lt; 17 years of age) with <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> at a dosage of 40 mg/kg every 8 hours. The types of clinical adverse events seen in these patients are similar to the adults, with the most common adverse events reported as possibly, probably, or definitely related to Meropenem for injection (I.V.) and their rates of occurrence as follows:</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> 4.7%</p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (mostly diaper area <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>) 3.1%</p>
<p><span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral Moniliasis</span> 1.9%</p>
<p><span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">Glossitis</span> 1%</p>
<p>In the <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> studies, the rates of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity during therapy were comparable between patients with no CNS abnormalities who received meropenem and those who received comparator agents (either cefotaxime or ceftriaxone). In the Meropenem for injection (I.V.) treated group, 12/15 patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> had late onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (defined as occurring on day 3 or later) versus 7/20 in the comparator arm.</p>
<p><span class="Bold">Adverse Laboratory Changes </span></p>
<p>Laboratory changes seen in the pediatric studies, including the <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> studies, were similar to those reported in the adult studies.</p>
<p>There is no experience in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2ee3e565-4b2d-4caf-91af-ac9cfdf995c1"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of Meropenem for injection (I.V.). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Worldwide post-marketing adverse reactions not otherwise listed in the Adverse Reactions section of this product label and reported as possibly, probably, or definitely drug related are listed within each body system in order of decreasing severity. Hematologic - <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>; a positive direct or indirect Coombs test, and <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>. Skin – <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_e929b349-3a79-441f-9ad7-2c7948c954d3"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_97f4b0d0-fd35-4526-9f7e-bb17234772cf"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Probenecid</h2>
<p class="First">Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem. Co-administration of probenecid with meropenem is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e5381a1d-23a1-46a6-a1b9-5e977d910c18"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Valproic Acid</h2>
<p class="First">Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Although the mechanism of this interaction is unknown, data from <span class="Italics">in vitro</span> and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid’s glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid. If administration of Meropenem for injection (I.V.) is necessary, then supplemental anti-convulsant therapy should be considered [<span class="Italics">see Warnings and Precautions</span> (<a href="#i4i_section_id_e50b455f-f975-4abe-8625-a2ab77af89f4">5.3</a>)].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_df177cda-7951-4b02-b2a9-2fd16d6c5e68"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_8b0a43ed-877e-4c9b-9132-ac76e236cad2"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B. Reproductive studies have been performed with meropenem in rats at doses of up to 1000 mg/kg/day, and cynomolgus monkeys at doses of up to 360 mg/kg/day (on the basis of AUC comparisons, approximately 1.8 times and 3.7 times, respectively, to the human exposure at the usual dose of 1 g every 8 hours). These studies revealed no evidence of impaired fertility or harm to the fetus due to meropenem, although there were slight changes in fetal body weight at doses of 250 mg/kg/day (on the basis of AUC comparisons, 0.4 times the human exposure at a dose of 1 g every 8 hours) and above in rats. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_2f917fe6-2e14-469a-89dc-1e2a767ee7a2"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Meropenem for injection (I.V.) is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_be7beb70-fa55-4414-8231-67fcbc246f88"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of Meropenem for injection (I.V.) have been established for pediatric patients ≥ 3 months of age. Use of Meropenem for injection (I.V.) in pediatric patients with <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">bacterial meningitis</span> is supported by evidence from adequate and well-controlled studies in the pediatric population. Use of Meropenem for injection (I.V.) in pediatric patients with intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> is supported by evidence from adequate and well-controlled studies with adults with additional data from pediatric pharmacokinetics studies and controlled clinical trials in pediatric patients. Use of Meropenem for injection (I.V.) in pediatric patients with complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is supported by evidence from an adequate and well-controlled study with adults and additional data from pediatric pharmacokinetics studies [<span class="Italics">see Indications and Usage</span> (<a href="#i4i_section_id_d5f51096-248e-4931-88dd-194e120fcdfa">1.3</a>), <span class="Italics">Dosage and Administration</span> (<a href="#i4i_section_id_c4ad8392-c23c-41d4-89e5-14580958e423">2.3</a>), <span class="Italics">Adverse Reactions</span> (<a href="#i4i_section_id_2c4a448d-6fe5-4a06-848d-725ba1696a5d">6.1</a>), <span class="Italics">Clinical Pharmacology</span> (<a href="#i4i_pharmacokinetics_id_ac6e3acf-3798-4404-a549-3d17d180f57c">12.3</a>) and <span class="Italics">Clinical Studies</span> (<a href="#i4i_section_id_3260dc44-ea26-4bcf-98e5-c04e3257c075">14.3</a>)].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_6b89a087-4cb1-434a-bd9c-96f237d4d68b"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects in clinical studies of Meropenem for injection (I.V.), approximately 1100 (30%) were 65 years of age and older, while 400 (11%) were 75 years and older. Additionally, in a study of 511 patients with complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, 93 (18%) were 65 years of age and older, while 38 (7%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects; spontaneous reports and other reported clinical experience have not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Meropenem is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
<p>A pharmacokinetic study with Meropenem for injection (I.V.) in elderly patients has shown a reduction in the plasma clearance of meropenem that correlates with age-associated reduction in creatinine clearance [<span class="Italics">see Clinical Pharmacology </span>(<a href="#i4i_pharmacokinetics_id_ac6e3acf-3798-4404-a549-3d17d180f57c">12.3</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3be5138-8fca-4c91-8fe6-58f96c048f1a"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage adjustment is necessary in patients with creatinine clearance 50 mL/min or less [<span class="Italics">see Dosage and Administration</span> (<a href="#i4i_section_id_6861e0dc-0096-47e3-bf61-8fc1ca0fca12">2.2</a>), <span class="Italics">Warnings and Precautions</span> (<a href="#i4i_section_id_c619beb9-ff65-45f0-a8f8-b827cc4c9e9c">5.8</a>), <span class="Italics">and Clinical Pharmacology </span>(<a href="#i4i_pharmacokinetics_id_ac6e3acf-3798-4404-a549-3d17d180f57c">12.3</a>)].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_ba139f06-0d89-40e8-973e-20e9f84908c9"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and mortalities.</p>
<p>Intentional overdosing of Meropenem for injection (I.V.) is unlikely, although accidental overdosing might occur if large doses are given to patients with reduced renal function. The largest dose of meropenem administered in clinical trials has been 2 g given intravenously every 8 hours. At this dosage, no adverse pharmacological effects or increased safety risks have been observed.</p>
<p>Limited post-marketing experience indicates that if adverse events occur following overdosage, they are consistent with the adverse event profile described in the Adverse Reactions section and are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered. In individuals with normal renal function, rapid renal elimination takes place. Meropenem and its metabolite are readily dialyzable and effectively removed by hemodialysis; however, no information is available on the use of hemodialysis to treat overdosage.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_060773af-ceea-4f5d-a8fb-83b45d675452"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Meropenem for Injection, USP (I.V.) is a sterile, pyrogen-free, synthetic, broad-spectrum, carbapenem antibiotic for intravenous administration. It is (4R,5S,6S)-3-[[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid trihydrate. Its empirical formula is C<span class="Sub">17</span>H<span class="Sub">25</span>N<span class="Sub">3</span>O<span class="Sub">5</span>S•3H<span class="Sub">2</span>O with a molecular weight of 437.52. Its structural formula is:</p>
<div class="Figure"><img alt="formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a68d899-2678-43a9-a9c1-ef8f916b562f&amp;name=00519448-d0ae-48e5-8921-5ddf5d87601e-01.jpg"></div>
<p>Meropenem for Injection, USP (I.V.) is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline powder. The solution varies from colorless to yellow depending on the concentration. The pH of freshly constituted solutions is between 7.3 and 8.3. Meropenem is soluble in 5% monobasic potassium phosphate solution, sparingly soluble in water, very slightly soluble in hydrated ethanol, and practically insoluble in acetone or ether.</p>
<p>When constituted as instructed, each 500 mg Meropenem for Injection, USP (I.V.) vial will deliver 500 mg meropenem and 45.1 mg of sodium as sodium carbonate (1.96 mEq). Each 1 g Meropenem for Injection, USP (I.V.) vial will deliver 1 g of meropenem and 90.2 mg of sodium as sodium carbonate (3.92 mEq). [<span class="Italics">see Dosage and Administration </span>(<a href="#i4i_section_id_c263ffdf-99c3-403c-a8c8-f01b3230b5ec">2.4</a>)].</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_1fdae3d3-f897-420a-9247-a677c086c3fb"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_d98cdf06-46aa-4086-b78e-87aed83fa180"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Meropenem is an antibacterial drug [<span class="Italics">see Clinical Pharmacology</span> (<a href="#i4i_section_id_dee7c6b6-a2da-4300-9b4c-6b1fa5fab56b">12.4</a>)].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_ac6e3acf-3798-4404-a549-3d17d180f57c"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<br><p class="First">Plasma Concentrations</p>
<p>At the end of a 30-minute intravenous infusion of a single dose of Meropenem for injection (I.V.) in healthy volunteers, mean peak plasma concentrations of meropenem are approximately 23 mcg/mL (range 14-26) for the 500 mg dose and 49 mcg/mL (range 39-58) for the 1 g dose. A 5-minute intravenous bolus injection of Meropenem for injection (I.V.) in healthy volunteers results in mean peak plasma concentrations of approximately 45 mcg/mL (range 18-65) for the 500 mg dose and 112 mcg/mL (range 83-140) for the 1 g dose.</p>
<p>Following intravenous doses of 500 mg, mean plasma concentrations of meropenem usually decline to approximately 1 mcg/mL at 6 hours after administration.</p>
<p>No accumulation of meropenem in plasma was observed with regimens using 500 mg administered every 8 hours or 1 g administered every 6 hours in healthy volunteers with normal renal function.</p>
<p><span class="Bold">Distribution</span></p>
<p>The plasma protein binding of meropenem is approximately 2%.</p>
<p>Meropenem penetrates well into most body fluids and tissues including cerebrospinal fluid, achieving concentrations matching or exceeding those required to inhibit most susceptible bacteria. After a single intravenous dose of Meropenem for injection (I.V.), the highest mean concentrations of meropenem were found in tissues and fluids at 1 hour (0.5 to 1.5 hours) after the start of infusion, except where indicated in the tissues and fluids listed in the table below.</p>
<br><br><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="5" valign="top">
<span class="Bold">Table 1. Meropenem Concentrations in Selected Tissues </span><br><span class="Bold">(Highest Concentrations Reported)</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Tissue <br>
</td>
<td class="Rrule" align="center" valign="top">I.V. Dose (g)<br>
</td>
<td class="Rrule" align="center" valign="top">Number of Samples <br>
</td>
<td class="Rrule" align="center" valign="top">Mean [mcg/mL or mcg/(g)]<span class="Italics"><span class="Sup">1</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">Range [mcg/mL or mcg/(g)]<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Endometrium <br>
</td>
<td class="Rrule" align="center" valign="top">0.5<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">4.2<br>
</td>
<td class="Rrule" align="center" valign="top">1.7-10.2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Myometrium <br>
</td>
<td class="Rrule" align="center" valign="top">0.5<br>
</td>
<td class="Rrule" align="center" valign="top">15<br>
</td>
<td class="Rrule" align="center" valign="top">3.8<br>
</td>
<td class="Rrule" align="center" valign="top">0.4-8.1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Ovary <br>
</td>
<td class="Rrule" align="center" valign="top">0.5<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">2.8<br>
</td>
<td class="Rrule" align="center" valign="top">0.8-4.8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Cervix <br>
</td>
<td class="Rrule" align="center" valign="top">0.5<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">5.4-8.5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Fallopian tube <br>
</td>
<td class="Rrule" align="center" valign="top">0.5<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">1.7<br>
</td>
<td class="Rrule" align="center" valign="top">0.3-3.4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Skin <br>
</td>
<td class="Rrule" align="center" valign="top">0.5<br>
</td>
<td class="Rrule" align="center" valign="top">22<br>
</td>
<td class="Rrule" align="center" valign="top">3.3<br>
</td>
<td class="Rrule" align="center" valign="top">0.5-12.6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Interstitial fluid<span class="Italics"><span class="Sup">2</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">0.5<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">5.5<br>
</td>
<td class="Rrule" align="center" valign="top">3.2-8.6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Skin <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">5.3<br>
</td>
<td class="Rrule" align="center" valign="top">1.3-16.7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Interstitial fluid<span class="Italics"><span class="Sup">2</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">26.3<br>
</td>
<td class="Rrule" align="center" valign="top">20.9-37.4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Colon <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">2.6<br>
</td>
<td class="Rrule" align="center" valign="top">2.5-2.7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Bile <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">14.6 (3 h)<br>
</td>
<td class="Rrule" align="center" valign="top">4-25.7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Gall bladder <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
<td class="Rrule" align="center" valign="top">3.9<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Peritoneal fluid <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">30.2<br>
</td>
<td class="Rrule" align="center" valign="top">7.4-54.6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Lung <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">4.8 (2 h)<br>
</td>
<td class="Rrule" align="center" valign="top">1.4-8.2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Bronchial mucosa <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">4.5<br>
</td>
<td class="Rrule" align="center" valign="top">1.3-11.1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Muscle <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">6. 1 (2 h)<br>
</td>
<td class="Rrule" align="center" valign="top">5.3-6.9<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Fascia <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">8.8 <br>
</td>
<td class="Rrule" align="center" valign="top">1.5-20<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Heart valves <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">9.7 <br>
</td>
<td class="Rrule" align="center" valign="top">6.4-12.1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Myocardium <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">15.5 <br>
</td>
<td class="Rrule" align="center" valign="top">5.2-25.5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">CSF (inflamed) <br>
</td>
<td class="Rrule" align="center" valign="top">20 mg/kg<span class="Italics"><span class="Sup">3</span></span><br>40 mg/kg<span class="Italics"><span class="Sup">4</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">8<br>5<br>
</td>
<td class="Rrule" align="center" valign="top">1.1 (2 h)<br>3.3 (3 h)<br>
</td>
<td class="Rrule" align="center" valign="top">0.2-2.8<br>0.9-6.5<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">CSF (uninflamed) <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">0.2 (2 h)<br>
</td>
<td class="Rrule" align="center" valign="top">0.1-0.3<br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">1</span> at 1 hour unless otherwise noted</p>
<p><span class="Sup">2 </span>obtained from <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid</p>
<p><span class="Sup">3</span> in pediatric patients of age 5 months to 8 years</p>
<p><span class="Sup">4 </span>in pediatric patients of age 1 month to 15 years</p>
<p><span class="Bold">Metabolism</span></p>
<p>There is one metabolite of meropenem that is microbiologically inactive.</p>
<p><span class="Bold">Excretion</span></p>
<p>In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour. </p>
<p>Meropenem is primarily excreted unchanged by the kidneys. Approximately 70% (50 – 75%) of the dose is excreted unchanged within 12 hours. A further 28% is recovered as the microbiologically inactive metabolite. Fecal elimination represents only approximately 2% of the dose. The measured renal clearance and the effect of probenecid show that meropenem undergoes both filtration and tubular secretion. </p>
<p>Urinary concentrations of meropenem in excess of 10 mcg/mL are maintained for up to 5 hours after a 500 mg dose.</p>
<br><br><p><span class="Bold">Specific Populations</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Pharmacokinetic studies with Meropenem for injection (I.V.) in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> have shown that the plasma clearance of meropenem correlates with creatinine clearance. Dosage adjustments are necessary in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance 50 mL/min or less) [<span class="Italics">see Dosage and Administration</span> (<a href="#i4i_section_id_6861e0dc-0096-47e3-bf61-8fc1ca0fca12">2.2</a>) and <span class="Italics">Use In Specific Populations</span> (<a href="#i4i_section_id_a3be5138-8fca-4c91-8fe6-58f96c048f1a">8.6</a>)].</p>
<p>Meropenem I.V. is hemodialyzable. However, there is no information on the usefulness of hemodialysis to treat overdosage [<span class="Italics">see Overdosage</span> (<a href="#i4i_overdosage_id_ba139f06-0d89-40e8-973e-20e9f84908c9">10</a>)].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>A pharmacokinetic study with Meropenem for injection (I.V.) in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has shown no effects of liver disease on the pharmacokinetics of meropenem.</p>
<p><span class="Bold">Geriatric Patients</span></p>
<p>A pharmacokinetic study with Meropenem for injection (I.V.) in elderly patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> showed a reduction in plasma clearance of meropenem that correlates with age-associated reduction in creatinine clearance.</p>
<p><span class="Bold">Pediatric Patients</span></p>
<p>The pharmacokinetics of meropenem in pediatric patients 2 years of age or older are essentially similar to those in adults. The elimination half-life for meropenem was approximately 1.5 hours in pediatric patients of age 3 months to 2 years. The pharmacokinetics are linear over the dose range from 10 to 40 mg/kg.</p>
<p><span class="Bold">Drug Interactions</span></p>
<p>Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. Following administration of probenecid with meropenem, the mean systemic exposure increased 56% and the mean elimination half-life increased 38%. Co-administration of probenecid with meropenem is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dee7c6b6-a2da-4300-9b4c-6b1fa5fab56b"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<br><p class="First"><span class="Underline">Mechanism of Action</span></p>
<p>The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of <span class="Italics">Escherichia coli</span> and <span class="Italics">Pseudomonas aeruginosa</span>; and PBPs 1, 2, and 4 of <span class="Italics">Staphylococcus aureus</span>. Bactericidal concentrations (defined as a 3 log<span class="Sub">10</span> reduction in cell counts within 12 to 24 hours) are typically 1-2 times the bacteriostatic concentrations of meropenem, with the exception of <span class="Italics">Listeria monocytogenes</span>, against which lethal activity is not observed.</p>
<p>Meropenem has significant stability to hydrolysis by β-lactamases, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria.</p>
<p>Meropenem should not be used to treat methicillin-resistant <span class="Italics">Staphylococcus aureus </span>(MRSA) or methicillin-resistant <span class="Italics">Staphylococcus epidermidis</span> (MRSE).</p>
<p><span class="Underline">Mechanism of Resistance </span></p>
<p>There are several mechanisms of resistance to carbapenems: 1) decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins) causing reduced bacterial uptake, 2) reduced affinity of the target PBPs, 3) increased expression of efflux pump components, and 4) production of antibiotic-destroying enzymes (carbapenemases, metallo-β-lactamases).  Localized clusters of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to carbapenem-resistant bacteria have been reported in some regions.</p>
<br><br><p><span class="Underline">Cross-Resistance </span></p>
<p>Cross-resistance is sometimes observed with isolates resistant to other carbapenems.</p>
<p><span class="Underline">Interactions with Other Antibiotics </span></p>
<p><span class="Italics">In vitro</span> tests show meropenem to act synergistically with aminoglycoside antibiotics against some isolates of <span class="Italics">Pseudomonas aeruginosa</span>.</p>
<p><span class="Underline">Spectrum of Activity </span></p>
<p>Meropenem has been shown to be active against most isolates of the following bacteria, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND USAGE section (<a href="#i4i_indications_id_4b200157-2177-4642-8389-deb16d3db58d">1</a>).</p>
<p><span class="Underline">Gram-positive bacteria</span></p>
<p><span class="Italics">Enterococcus faecalis </span>(vancomycin-susceptible isolates only)</p>
<p><span class="Italics">Staphylococcus aureus</span> (methicillin-susceptible isolates only)</p>
<p><span class="Italics">Streptococcus agalactiae </span></p>
<p><span class="Italics">Streptococcus pneumoniae</span> (penicillin-susceptible isolates only)</p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p>Viridans group streptococci</p>
<p><span class="Underline">Gram-negative bacteria</span></p>
<p><span class="Italics">Escherichia coli </span></p>
<p><span class="Italics">Haemophilus influenzae</span></p>
<p><span class="Italics">Klebsiella pneumoniae </span></p>
<p><span class="Italics">Neisseria meningitidis </span></p>
<p><span class="Italics">Pseudomonas aeruginosa </span></p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p><span class="Underline">Anaerobic bacteria</span></p>
<p><span class="Italics">Bacteroides fragilis </span></p>
<p><span class="Italics">Bacteroides thetaiotaomicron </span></p>
<p><span class="Italics">Peptostreptococcus </span>species</p>
<p>The following <span class="Italics">in vitro</span> data are available, but their clinical significance is unknown. At least 90% of the following bacteria have exhibited <span class="Italics">in vitro </span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoints for meropenem. However, the safety and effectiveness of meropenem in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria have not been established in adequate and well-controlled trials.</p>
<p><span class="Underline">Gram-positive bacteria</span></p>
<p><span class="Italics">Staphylococcus epidermidis</span> (methicillin-susceptible isolates only)</p>
<br><p><span class="Underline">Gram-negative bacteria</span></p>
<br><p><span class="Italics">Aeromonas hydrophila</span></p>
<p><span class="Italics">Campylobacter jejuni</span></p>
<p><span class="Italics">Citrobacter koseri (</span>formerly<span class="Italics"> diversus)</span></p>
<p><span class="Italics">Citrobacter freundii</span><span class="Italics"></span></p>
<p><span class="Italics">Enterobacter cloacae</span></p>
<p><span class="Italics">Hafnia alvei</span></p>
<p><span class="Italics">Klebsiella oxytoca</span></p>
<p><span class="Italics">Moraxella catarrhalis </span></p>
<p><span class="Italics">Morganella morganii</span><span class="Underline"></span></p>
<p><span class="Italics">Pasteurella multocida</span><span class="Underline"></span></p>
<p><span class="Italics">Proteus vulgaris</span></p>
<p><span class="Italics">Serratia marcescens</span><span class="Underline"></span></p>
<p><span class="Underline">Anaerobic bacteria</span></p>
<p><span class="Italics">Bacteroides distasonis </span></p>
<p><span class="Italics">Bacteroides ovatus </span></p>
<p><span class="Italics">Bacteroides uniformis </span></p>
<p><span class="Italics">Bacteroides ureolyticus</span></p>
<p><span class="Italics">Bacteroides vulgatus </span></p>
<p><span class="Italics">Clostridium difficile </span></p>
<p><span class="Italics">Clostridium perfringens </span></p>
<p><span class="Italics">Eubacterium lentum</span></p>
<p><span class="Italics">Fusobacterium</span> species<span class="Italics"></span></p>
<p><span class="Italics">Prevotella bivia</span></p>
<p><span class="Italics">Prevotella intermedia</span></p>
<p><span class="Italics">Prevotella melaninogenica</span></p>
<p><span class="Italics">Porphyromonas asaccharolytica</span></p>
<p><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></p>
<p><span class="Underline">Susceptibility Test Methods</span></p>
<p>When available, the clinical microbiology laboratory should provide cumulative results of <span class="Italics">in vitro </span>susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.</p>
<p><span class="Underline">Dilution Techniques:</span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method. Standardized procedures are based on a dilution method<span class="Sup">1,3 </span>(broth or agar) or equivalent using standardized inoculum concentrations and standardized concentrations of meropenem powder. The MIC values should be interpreted according to the criteria provided in Table 2.</p>
<p><span class="Underline">Diffusion Techniques:</span></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method <span class="Sup">2,3</span> and requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 10-mcg of meropenem to test the susceptibility of microorganisms to meropenem. The disk diffusion interpretive criteria are provided in Table 2.</p>
<br><br><p><span class="Underline">Anaerobic Techniques:</span></p>
<p>For anaerobic bacteria, the susceptibility to meropenem as MICs can be determined by a standardized test method.<span class="Sup">2,4 </span>The MIC values obtained should be interpreted according to the criteria provided in Table 2.</p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="border-collapse: collapse"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="7" valign="top">
<span class="Bold">Table 2. Susceptibility Interpretive Criteria for Meropenem</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" colspan="3" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/mL)</span><br>
</td>
<td class="Rrule" align="center" colspan="3" valign="top">
<span class="Bold">Disk Diffusion</span><br><span class="Bold">(zone diameters in mm)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Pathogen </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">S</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">I</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">R</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">S</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">I</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">R</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Enterobacteriaceae, </span><br>
</td>
<td class="Rrule" align="center" valign="top">≤ 1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">≥ 4<br>
</td>
<td class="Rrule" align="center" valign="top">≥ 23<br>
</td>
<td class="Rrule" align="center" valign="top">20-22<br>
</td>
<td class="Rrule" align="center" valign="top">≤ 19<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Pseudomonas aeruginosa</span><br>
</td>
<td class="Rrule" align="center" valign="top">≤ 4<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">≥ 16<br>
</td>
<td class="Rrule" align="center" valign="top">≥ 16<br>
</td>
<td class="Rrule" align="center" valign="top">14-15<br>
</td>
<td class="Rrule" align="center" valign="top">≤ 13<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus influenzae<span class="Sup">a</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">≤ 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">≥ 20<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Neisseria meningitidis<span class="Sup">a</span></span><span class="Sup"></span><br>
</td>
<td class="Rrule" align="center" valign="top">≤ 0.25<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">≥ 30<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Streptococcus pneumoniae</span><span class="Italics"><span class="Sup">b,d</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">≤ 0.25<br>
</td>
<td class="Rrule" align="center" valign="top">0.5<br>
</td>
<td class="Rrule" align="center" valign="top">≥ 1<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Streptococcus agalactiae</span> and <span class="Italics">Streptococcus pyogenes<span class="Sup">a,c,d</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">≤ 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Anaerobes<span class="Italics"><span class="Sup">e</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">≤ 4<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">≥ 16<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
<td class="Rrule" align="center" valign="top">--<br>
</td>
</tr>
</tbody></table>
<p>S = Susceptible, I = Intermediate, R = Resistant</p>
<p>No interpretative criteria have been established for testing enterococci .</p>
<p>Susceptibility of staphylococci to meropenem may be deduced from testing penicillin and either cefoxitin or oxacillin.</p>
<p><span class="Sup">a</span>The current absence of data on resistant isolates precludes defining any category other than “Susceptible?. If isolates yield MIC results other than susceptible, they should be submitted to a reference laboratory for additional testing.</p>
<p><span class="Sup">b </span>Interpretative criteria in Table 2 should only be used for isolates from CSF. For nonmeningitis isolates of <span class="Italics">Streptococcus pneumoniae </span>a penicillin MIC of ≤ 0.06 mcg/mL or oxacillin zone ≥ 20 mm can predict susceptibility to meropenem. MIC testing should be performed on isolates that do not test as susceptible by either of these methods, and on all <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> <span class="Italics"> S. pneumoniae </span>isolates.</p>
<p><span class="Sup">c </span>Viridans group streptococci should be tested for meropenem susceptibility using an MIC method</p>
<p><span class="Sup">d</span> Reliable disk diffusion tests for meropenem do not yet exist for testing streptococci</p>
<p><span class="Sup">e  </span>MIC values using either Brucella blood or Wilkins Chalgren agar (former reference medium) are considered equivalent, based upon published <span class="Italics">in vitro </span>literature and a multicenter collaborative trial for these antimicrobial agents.</p>
<p>A report of <span class="Italics">Susceptible</span> indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of <span class="Italics">Intermediate </span>indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of <span class="Italics">Resistant</span> indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p><span class="Underline">Quality Control</span></p>
<p>Standardized susceptibility test procedures require the use of quality controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test. Standard meropenem powder should provide the following range of values noted in Table 3. </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="3" valign="top">
<span class="Bold">Table 3. Acceptable Quality Control Ranges for Meropenem</span><span class="Bold"></span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (MICs =mcg/mL)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Disk Diffusion</span><br><span class="Bold">(Zone diameters in mm)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Staphylococcus aureus</span><br>ATCC 29213<br>
</td>
<td class="Rrule" align="center" valign="top">0.03-0.12<br>
</td>
<td class="Rrule" align="center" valign="top">___________<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Staphylococcus aureus</span><br>ATCC 25923<br>
</td>
<td class="Rrule" align="center" valign="top">______________<br>
</td>
<td class="Rrule" align="center" valign="top">29-37<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Streptococcus pneumoniae</span><br>ATCC 49619<br>
</td>
<td class="Rrule" align="center" valign="top">0.06-0.25<br>
</td>
<td class="Rrule" align="center" valign="top">28-35<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Enterococcus faecalis</span><br>ATCC 29212<br>
</td>
<td class="Rrule" align="center" valign="top">2-8<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Escherichia coli</span><br>ATCC 25922<br>
</td>
<td class="Rrule" align="center" valign="top">0.008-0.06<br>
</td>
<td class="Rrule" align="center" valign="top">28-34<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus influenzae</span><br>ATCC 49766<br>
</td>
<td class="Rrule" align="center" valign="top">0.03-0.12<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus influenzae</span><br>ATCC 49247<br>
</td>
<td class="Rrule" align="center" valign="top">________________<br>
</td>
<td class="Rrule" align="center" valign="top">20-28<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Pseudomonas aeruginosa</span><br>ATCC 27853<br>
</td>
<td class="Rrule" align="center" valign="top">0.25-1<br>
</td>
<td class="Rrule" align="center" valign="top">27-33<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Bacteroides fragilis</span><span class="Italics"><span class="Sup">1</span></span><br>ATCC 25285<br>
</td>
<td class="Rrule" align="center" valign="top">0.03-0.25<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Bacteroides thetaiotaomicron</span><span class="Italics"><span class="Sup">1</span></span><br>ATCC 29741<br>
</td>
<td class="Rrule" align="center" valign="top">0.125-0.5<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Eubacterium lentum</span><span class="Italics"><span class="Sup">1</span></span><br>ATCC 43055<br>
</td>
<td class="Rrule" align="center" valign="top">0.125-1<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">1</span>Using the Reference Agar Dilution procedure.</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_14153942-d305-4474-981f-70182383e226"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_94a04192-5aff-4fb6-9993-3ee1c04d564b"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">Carcinogenesis:</span></p>
<p>Carcinogenesis studies have not been performed.</p>
<p><span class="Italics">Mutagenesis: </span></p>
<p>Genetic toxicity studies were performed with meropenem using the bacterial reverse mutation test, the Chinese hamster ovary HGPRT assay, cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> cytogenic assay, and the mouse micronucleus test. There was no evidence of mutagenic potential found in any of these tests.</p>
<p><span class="Italics">Impairment of Fertility:</span></p>
<p>Reproductive studies were performed with meropenem in rats at doses up to 1000 mg/kg/day, and cynomolgus monkeys at doses up to 360 mg/kg/day (on the basis of AUC comparisons, approximately 1.8 times and 3.7 times, respectively, to the human exposure at the usual dose of 1 g every 8 hours). There was no reproductive toxicity seen.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_66c2bbda-1b17-40c7-add2-fdc623f5fd0a"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c49beb33-351f-4a40-8d20-8b40814ad1a0"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Adult patients with complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> including complicated <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, complex <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, <span class="product-label-link" type="condition" conceptid="4241157" conceptname="Perirectal abscess">perirectal abscesses</span>, and <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> requiring intravenous antimicrobials, hospitalization, and <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span> were enrolled in a randomized, multi-center, international, double-blind trial. The study evaluated meropenem at doses of 500 mg administered intravenously every 8 hours and imipenem-cilastatin at doses of 500 mg administered intravenously every 8 hours. The study compared the clinical response between treatment groups in the clinically evaluable population at the follow-up visit (test-of-cure). The trial was conducted in the United States, South Africa, Canada, and Brazil. At enrollment, approximately 37% of the patients had underlying <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, 12% had underlying <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> and 67% had a <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>. The study included 510 patients randomized to meropenem and 527 patients randomized to imipenem-cilastatin. Two hundred and sixty-one (261) patients randomized to meropenem and 287 patients randomized to imipenem-cilastatin were clinically evaluable. The success rates in the clinically evaluable patients at the follow-up visit were 86% (225/261) in the meropenem arm and 83% (238/287) in imipenem-cilastatin arm.</p>
<br><p>The following table provides the results for the overall as well as subgroup comparisons in clinically evaluable population. </p>
<br><a name="id_0058e33c-b5dd-479b-9d04-a8d0f5b9d436"></a><table border="0" cellpadding="0" cellspacing="0" width="325"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="3" valign="top">Success Rate<span class="Italics"><span class="Sup">1</span></span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Population<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>Meropenem for injection (I.V.)<br> <br>            n<span class="Italics"><span class="Sup">2</span></span>/N<span class="Italics"><span class="Sup">3</span></span> (%)            <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>Imipenem-cilastatin<br> <br>            n<span class="Italics"><span class="Sup">2</span></span>/N<span class="Italics"><span class="Sup">3</span></span> (%)            <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Total<br>
</td>
<td class="Rrule" align="center" valign="top">225/261 (86)<br>
</td>
<td class="Rrule" align="center" valign="top">238/287 (83)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus <br>
</td>
<td class="Rrule" align="center" valign="top">83/97 (86)<br>
</td>
<td class="Rrule" align="center" valign="top">76/105 (72)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">No <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus <br>
</td>
<td class="Rrule" align="center" valign="top">142/164 (87)<br>
</td>
<td class="Rrule" align="center" valign="top">162/182 (89)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">&lt; 65 years of age <br>
</td>
<td class="Rrule" align="center" valign="top">190/218 (87)<br>
</td>
<td class="Rrule" align="center" valign="top">205/241 (85)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">≥ 65 years of age <br>
</td>
<td class="Rrule" align="center" valign="top">35/43 (81)<br>
</td>
<td class="Rrule" align="center" valign="top">33/46 (72)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">Men <br>
</td>
<td class="Rrule" align="center" valign="top">130/148 (88)<br>
</td>
<td class="Rrule" align="center" valign="top">137/172 (80)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">Women <br>
</td>
<td class="Rrule" align="center" valign="top">95/113 (84)<br>
</td>
<td class="Rrule" align="center" valign="top">101/115 (88)<br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">1</span> Percent of satisfactory clinical response at follow-up evaluation.</p>
<br><p><span class="Sup">2</span> n = number of patients with satisfactory response.</p>
<br><p><span class="Sup">3</span> N = number of patients in the clinically evaluable population or respective subgroup within treatment groups.</p>
<br><p>The following clinical efficacy rates were obtained, per organism. The values represent the number of patients clinically cured/number of clinically evaluable patients at the post-treatment follow-up visit, with the percent cure in parentheses (Fully Evaluable analysis set). </p>
<br><a name="id_a4f83087-23b9-47ba-b304-2e9087f41652"></a><table border="0" cellpadding="0" cellspacing="0" width="374"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">MICROORGANISMS<span class="Italics"><span class="Sup">1</span></span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>Meropenem for injection (I.V.)<br> <br>            n<span class="Italics"><span class="Sup">2</span></span>/N<span class="Italics"><span class="Sup">3</span></span> (%)<span class="Italics"><span class="Sup">4</span></span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>Imipenem-cilastatin<br> <br>            n<span class="Italics"><span class="Sup">2</span></span>/N<span class="Italics"><span class="Sup">3</span></span> (%)<span class="Italics"><span class="Sup">4</span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Bold">Gram-positive aerobes </span><br>
</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top"> <br><span class="Italics">Staphylococcus aureus,</span><br> <br>            methicillin susceptible            <br>
</td>
<td class="Rrule" align="center" valign="top">82/88 (93)<br>
</td>
<td class="Rrule" align="center" valign="top">84/100 (84)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">Streptococcus pyogenes </span>(Group A) <br>
</td>
<td class="Rrule" align="center" valign="top">26/29 (90)<br>
</td>
<td class="Rrule" align="center" valign="top">28/32 (88)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">Streptococcus agalactiae </span>(Group B) <br>
</td>
<td class="Rrule" align="center" valign="top">12/17 (71)<br>
</td>
<td class="Rrule" align="center" valign="top">16/19 (84)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">Enterococcus faecalis </span><br>
</td>
<td class="Rrule" align="center" valign="top">9/12 (75)<br>
</td>
<td class="Rrule" align="center" valign="top">14/20 (70)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">Streptococcus </span>viridans Group, nos<br>
</td>
<td class="Rrule" align="center" valign="top">11/12 (92)<br>
</td>
<td class="Rrule" align="center" valign="top">5/6 (83)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Bold">Gram-negative aerobes </span><br>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">Escherichia coli </span><br>
</td>
<td class="Rrule" align="center" valign="top">12/15 (80)<br>
</td>
<td class="Rrule" align="center" valign="top">15/21 (71)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">Pseudomonas aeruginosa </span><br>
</td>
<td class="Rrule" align="center" valign="top">11/15 (73)<br>
</td>
<td class="Rrule" align="center" valign="top">13/15 (87)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">Proteus mirabilis </span><br>
</td>
<td class="Rrule" align="center" valign="top">11/13 (85)<br>
</td>
<td class="Rrule" align="center" valign="top">6/7 (86)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Bold">Anaerobes </span><br>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">Bacteroides fragilis </span><br>
</td>
<td class="Rrule" align="center" valign="top">10/11 (91)<br>
</td>
<td class="Rrule" align="center" valign="top">9/10 (90)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">Peptostreptococcus </span>species <br>
</td>
<td class="Rrule" align="center" valign="top">10/13 (77)<br>
</td>
<td class="Rrule" align="center" valign="top">14/16 (88)<br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">1</span> Patients may have more than one pretreatment pathogen.</p>
<br><p><span class="Sup">2 </span>n = number of patients with satisfactory response.</p>
<br><p><span class="Sup">3 </span>N = number of patients in the clinically evaluable population or subgroup within treatment groups.</p>
<br><p><span class="Sup">4 </span>% = Percent of satisfactory clinical response at follow-up evaluation.</p>
<br><p>The proportion of patients who discontinued study treatment due to an adverse event was similar for both treatment groups (meropenem, 2.5% and imipenem-cilastatin, 2.7%).</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f0d390b3-53b0-4e1c-839b-50d6ff950f34"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></h2>
<p class="First">One controlled cli<span class="Sup">n</span>ical study of complicated intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infection</span> was performed in the United States where meropenem was compared with clindamycin/tobramycin. Three controlled clinical studies of complicated intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> were performed in Europe; meropenem was compared with imipenem (two trials) and cefotaxime/metronidazole (one trial).</p>
<p>Using strict evaluability criteria and microbiologic eradication and clinical cures at follow-up which occurred 7 or more days after completion of therapy, the following presumptive microbiologic eradication/clinical cure rates and statistical findings were obtained: </p>
<a name="id_402fe707-0d6e-4162-b15f-21b922748dc5"></a><table border="0" cellpadding="0" cellspacing="0" width="399.000"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Treatment Arm</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">No. evaluable/ No. enrolled (%)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Microbiologic Eradication Rate</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Clinical Cure Rate</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Outcome</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">meropenem<br>
</td>
<td class="Rrule" align="left" valign="top">146/516 (28%)<br>
</td>
<td class="Rrule" align="left" valign="top">98/146 (67%)<br>
</td>
<td class="Rrule" align="left" valign="top">101/146 (69%)<br>
</td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">imipenem<br>
</td>
<td class="Rrule" align="left" valign="top">65/220 (30%)<br>
</td>
<td class="Rrule" align="left" valign="top">40/65 (62%)<br>
</td>
<td class="Rrule" align="left" valign="top">42/65 (65%)<br>
</td>
<td class="Rrule" align="left" valign="top">Meropenem equivalent to control <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">cefotaxime/ metronidazole <br>
</td>
<td class="Rrule" align="left" valign="top">26/85 (30%)<br>
</td>
<td class="Rrule" align="left" valign="top">22/26 (85%)<br>
</td>
<td class="Rrule" align="left" valign="top">22/26 (85%)<br>
</td>
<td class="Rrule" align="left" valign="top">Meropenem not equivalent to control <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">clindamycin/ tobramycin <br>
</td>
<td class="Rrule" align="left" valign="top">50/212 (24%)<br>
</td>
<td class="Rrule" align="left" valign="top">38/50 (76%)<br>
</td>
<td class="Rrule" align="left" valign="top">38/50 (76%)<br>
</td>
<td class="Rrule" align="left" valign="top">Meropenem equivalent to control <br>
</td>
</tr>
</tbody></table>
<p>The finding that meropenem was not statistically equivalent to cefotaxime/metronidazole may have been due to uneven assignment of more seriously ill patients to the meropenem arm. Currently there is no additional information available to further interpret this observation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3260dc44-ea26-4bcf-98e5-c04e3257c075"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">Bacterial Meningitis</span></h2>
<p class="First">Four hundred forty-six patients (397 pediatric patients ≥ 3 months to &lt; 17 years of age) were enrolled in 4 separate clinical trials and randomized to treatment with meropenem (n = 225) at a dose of 40 mg/kg every 8 hours or a comparator drug, i.e., cefotaxime (n = 187) or ceftriaxone (n = 34), at the approved dosing regimens. A comparable number of patients were found to be clinically evaluable (ranging from 61-68%) and with a similar distribution of pathogens isolated on initial CSF culture.</p>
<br><p>Patients were defined as clinically not cured if any one of the following three criteria were met:</p>
<br><ol class="Arabic">
<li>At the 5-7 week post-completion of therapy visit, the patient had any one of the following: moderate to severe motor, behavior or development deficits, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> of &gt; 60 decibels in one or both ears, or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>.</li>
<li>During therapy the patient’s clinical status necessitated the addition of other antibiotics.</li>
<li>Either during or post-therapy, the patient developed a large subdural <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span> needing surgical drainage, or a cerebral <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, or a bacteriologic relapse.</li>
</ol>
<p>Using the definition, the following efficacy rates were obtained, per organism. The values represent the number of patients clinically cured/number of clinically evaluable patients, with the percent cure in parentheses. </p>
<br><a name="id_447bd93b-28d6-40f7-9856-d737123767ae"></a><table border="0" cellpadding="0" cellspacing="0" width="304"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Bold">MICROORGANISMS</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">MEROPENEM FOR INJECTION (I.V.)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">COMPARATOR</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">S. pneumoniae</span><br>
</td>
<td class="Rrule" align="center" valign="top">17/24 (71)<br>
</td>
<td class="Rrule" align="center" valign="top">19/30 (63)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">H. influenzae </span>(+) <span class="Sup">1</span><br>
</td>
<td class="Rrule" align="center" valign="top">8/10 (80)<br>
</td>
<td class="Rrule" align="center" valign="top">6/6 (100)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">H. influenzae</span> (-/NT)<span class="Sup"> 2</span><br>
</td>
<td class="Rrule" align="center" valign="top">44/59 (75)<br>
</td>
<td class="Rrule" align="center" valign="top">44/60 (73)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Italics">N. meningitidis</span><br>
</td>
<td class="Rrule" align="center" valign="top">30/35 (86)<br>
</td>
<td class="Rrule" align="center" valign="top">35/39 (90)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">Total (including others)<br>
</td>
<td class="Rrule" align="center" valign="top">102/131 (78)<br>
</td>
<td class="Rrule" align="center" valign="top">108/140 (77)<br>
</td>
</tr>
</tbody></table>
<p> <span class="Sup">1</span>(+) β-lactamase-producing  </p>
<br><p><span class="Sup">2</span>(-/NT) non-β-lactamase-producing or not tested</p>
<br><p>Sequelae were the most common reason patients were assessed as clinically not cured.</p>
<br><p>Five patients were found to be bacteriologically not cured, 3 in the comparator group (1 relapse and 2 patients with cerebral <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>) and 2 in the meropenem group (1 relapse and 1 with continued growth of <span class="Italics">Pseudomonas aeruginosa</span>).</p>
<br><p>The adverse events seen were comparable between the two treatment groups both in type and frequency. The meropenem group did have a statistically higher number of patients with transient elevation of liver enzymes [<span class="Italics">see Adverse Reactions</span> (6.1)]. Rates of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity during therapy were comparable between patients with no CNS abnormalities who received meropenem and those who received comparator agents. In the Meropenem for injection (I.V.) treated group, 12/15 patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> had late onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (defined as occurring on day 3 or later) versus 7/20 in the comparator arm.</p>
<br><p>With respect to <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, 263 of the 271 evaluable patients had at least one hearing test performed post-therapy. The following table shows the degree of <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> between the meropenem-treated patients and the comparator-treated patients. </p>
<br><a name="id_64ffa967-1250-45e1-8d2c-b748c35f1b95"></a><table border="0" cellpadding="0" cellspacing="0" width="283"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top"> <br><span class="Bold">Degree of <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing Loss</span></span><br> <br><span class="Bold">(in one or both ears)</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Meropenem</span><br> <br><span class="Bold">n = 128</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br><span class="Bold">Comparator</span><br> <br><span class="Bold">n = 135</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">No loss <br>
</td>
<td class="Rrule" align="center" valign="top">61%<br>
</td>
<td class="Rrule" align="center" valign="top">56%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">20-40 decibels<br>
</td>
<td class="Rrule" align="center" valign="top">20%<br>
</td>
<td class="Rrule" align="center" valign="top">24%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">&gt; 40-60 decibels<br>
</td>
<td class="Rrule" align="center" valign="top">8%<br>
</td>
<td class="Rrule" align="center" valign="top">7%<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">&gt; 60 decibels<br>
</td>
<td class="Rrule" align="center" valign="top">9%<br>
</td>
<td class="Rrule" align="center" valign="top">10%<br>
</td>
</tr>
</tbody></table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_aeed30da-c337-4811-92f7-64c98ae490df"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition</span>. CLSI  document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500,  Wayne, Pennsylvania 19087, USA, 2012.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Eleventh Edition </span>CLSI document M02-A11,  Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne,  Pennsylvania 19087, USA, 2012.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-third Informational Supplement</span>, CLSI document M100-S23. CLSI  document M100-S23, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2013</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - Eighth Edition</span>. CLSI document M11-A8.  Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087  USA, 2012</li>
<li>Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.</li>
</ol>
<br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_428aed26-ca2c-49b1-88b6-8441015a6a8a"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Meropenem for Injection, USP (I.V.) is supplied in 20 mL and 30 mL injection vials containing sufficient meropenem to deliver 500 mg or 1 g for intravenous administration, respectively. The dry powder should be stored at controlled room temperature 20-25ºC (68-77ºF) [see USP].</p>
<a name="id_ca64338f-1275-49c3-b653-ff257dfa1f1f"></a><table border="0" cellpadding="0" cellspacing="0" width="0.000"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Bold">Product<br>             No.</span><br>
</td>
<td class="Rrule" align="left" valign="top">
<span class="Bold">NDC <br>            No.</span><br>
</td>
<td class="Rrule" align="left" valign="top">
<span class="Bold">Strength</span><br>
</td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top">PRX350725<br>
</td>
<td class="Rrule" align="left" valign="top">63323-507-25<br>
</td>
<td class="Rrule" align="left" valign="top">500 mg/vial <br>
</td>
<td class="Rrule" align="left" valign="top">Injection Vial packaged in cartons of 25<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">PRX350825<br>
</td>
<td class="Rrule" align="left" valign="top">63323-508-25<br>
</td>
<td class="Rrule" align="left" valign="top">1 g/vial <br>
</td>
<td class="Rrule" align="left" valign="top">Injection Vial packaged in cartons of 25<br>
</td>
</tr>
</tbody></table>
<p>This container closure is not made with natural rubber latex.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_37eff123-4599-4648-abfb-97dad28c5cb5"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<ul class="Disc">
<li>Patients should be counseled that antibacterial drugs including Meropenem for injection (I.V.) should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Meropenem for injection (I.V.) is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Meropenem for injection (I.V.) or other antibacterial drugs in the future.</li>
<li>Patients should be counseled that <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible [see <span class="Italics">Warnings and Precautions</span> (<a href="#i4i_section_id_065c9412-d801-440d-83ba-8319218e44bc">5.4</a>)].</li>
<li>Patients should be counseled to inform their physician if they are taking valproic acid or divalproex sodium. Valproic acid concentrations in the blood may drop below the therapeutic range upon co-administration with Meropenem for injection (I.V.). If treatment with Meropenem for injection (I.V.) is necessary and continued, alternative or supplemental anti-convulsant medication to prevent and/or treat <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may be needed [see <span class="Italics">Warnings and Precautions </span>(<a href="#i4i_section_id_e50b455f-f975-4abe-8625-a2ab77af89f4">5.3</a>)].</li>
<li>Patients receiving Meropenem for injection (I.V.) on an outpatient basis may develop adverse events such as <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and/or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> that could interfere with mental alertness and/or cause motor impairment. Until it is reasonably well established that Meropenem for injection (I.V.) is well tolerated, patients should not operate machinery or motorized vehicles [see<span class="Italics"> Warnings and Precautions </span>(<a href="#i4i_section_id_162fbfa3-2777-46ce-a45d-68facaefe5df">5.10</a>)].</li>
</ul>
<p class="First">NORMOSOL is a registered trademark of Hospira Inc.<br><br>PREMIERPro<span class="Sup">™</span> Rx is a trademark of Premier, Inc., used under license.</p>
<p>Manufactured for:</p>
<p><span class="Bold">Fresenius Kabi USA, LLC</span></p>
<p>Lake Zurich, IL 60047</p>
<p>Issued: June 2014<br><br><img alt="premier" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a68d899-2678-43a9-a9c1-ef8f916b562f&amp;name=prx-logo.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_fd39f38a-16a2-4f32-8fb5-aba5a756db51"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL- PRINCIPAL DISPLAY - Meropenem 500 mg Single Use Vial Label<br>NDC</span> 63323-507-25<br>PRX350725<br><span class="Bold">Meropenem for Injection, USP (I.V.)<br>500 mg/vial meropenem equivalent<br></span>Each vial contains: Meropenem equivalent to 500 mg meropenem activity.  <br>The sodium content is approximately 45.1 mg (1.96 mEq).<br>For Intravenous Use Only<br>Contents are Sterile         Rx only</p>
<br><br><div class="Figure"><img alt="prx350725" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a68d899-2678-43a9-a9c1-ef8f916b562f&amp;name=prx350725-vial.jpg"></div>
<br><br><br><p><span class="Bold">PACKAGE LABEL- PRINCIPAL DISPLAY - Meropenem 500 mg Single Use Vial Carton Panel<br>NDC</span> 63323-507-25<br>PRX350725<br><span class="Bold">Meropenem for Injection, USP (I.V.)<br>500 mg/vial meropenem equivalent<br></span>Each vial contains: Meropenem equivalent to 500 mg meropenem activity.  <br>The sodium content is approximately 45.1 mg (1.96 mEq).<br>For Intravenous Use Only<br>Contains: 25 x <span class="Bold">500 mg</span> sterile vials<br>Rx only</p>
<br><div class="Figure"><img alt="prx350725" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a68d899-2678-43a9-a9c1-ef8f916b562f&amp;name=prx350725-pbox.jpg"></div>
<br><br><br><br><p><span class="Bold">PACKAGE LABEL- PRINCIPAL DISPLAY - Meropenem 1 gram Single Use Vial Label<br>NDC</span> 63323-508-25<br>PRX350825<br><span class="Bold">Meropenem for Injection, USP (I.V.)<br>1 gram/vial meropenem equivalent<br></span>Each vial contains: Meropenem equivalent to 1 g meropenem activity.  <br>The sodium content is approximately 90.2 mg (3.92 mEq).<br>For Intravenous Use Only<br>Contents are Sterile         Rx only</p>
<br><br><div class="Figure"><img alt="prx350825" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a68d899-2678-43a9-a9c1-ef8f916b562f&amp;name=prx350825-vial.jpg"></div>
<br><br><br><br><p><span class="Bold">PACKAGE LABEL- PRINCIPAL DISPLAY - Meropenem 1 gram Single Use Vial Carton Panel<br>NDC</span> 63323-508-25<br>PRX350825<br><span class="Bold">Meropenem for Injection, USP (I.V.)<br>1 gram/vial meropenem equivalent<br></span>Each vial contains: Meropenem equivalent to 1 g meropenem activity.  <br>The sodium content is approximately 90.2 mg (3.92 mEq).<br>For Intravenous Use Only<br>Contains: 25 x <span class="Bold">1 g</span> sterile vials<br>Rx only</p>
<br><br><div class="Figure"><img alt="prx350825" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a68d899-2678-43a9-a9c1-ef8f916b562f&amp;name=prx350825-pbox.jpg"></div>
<br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MEROPENEM 		
					</strong><br><span class="contentTableReg">meropenem injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-507</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MEROPENEM</strong> (MEROPENEM ANHYDROUS) </td>
<td class="formItem">MEROPENEM</td>
<td class="formItem">500 mg  in 10 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-507-25</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091404</td>
<td class="formItem">10/14/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MEROPENEM 		
					</strong><br><span class="contentTableReg">meropenem injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-508</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MEROPENEM</strong> (MEROPENEM ANHYDROUS) </td>
<td class="formItem">MEROPENEM</td>
<td class="formItem">1 g  in 20 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-508-25</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091404</td>
<td class="formItem">10/26/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Facta Farmaceutici SPA</td>
<td class="formItem"></td>
<td class="formItem">430264268</td>
<td class="formItem">API MANUFACTURE(63323-507, 63323-508), MANUFACTURE(63323-507, 63323-508)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Zambon Switerland Ltd</td>
<td class="formItem"></td>
<td class="formItem">481761344</td>
<td class="formItem">MANUFACTURE(63323-507, 63323-508)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7a68d899-2678-43a9-a9c1-ef8f916b562f</div>
<div>Set id: 7a68d899-2678-43a9-a9c1-ef8f916b562f</div>
<div>Version: 1</div>
<div>Effective Time: 20141204</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
